BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 28338656)

  • 1. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
    Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
    Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma.
    Francalanci P; Giovannoni I; De Stefanis C; Romito I; Grimaldi C; Castellano A; D'Oria V; Alaggio R; Alisi A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.
    Gao SB; Zheng QF; Xu B; Pan CB; Li KL; Zhao Y; Zheng QL; Lin X; Xue LX; Jin GH
    Mol Cancer Res; 2014 Oct; 12(10):1388-97. PubMed ID: 24916103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
    Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
    Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axis.
    Chen S; Wang G; Tao K; Cai K; Wu K; Ye L; Bai J; Yin Y; Wang J; Shuai X; Gao J; Pu J; Li H
    Cancer Sci; 2020 May; 111(5):1582-1595. PubMed ID: 32129914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of CTCF reduces the binding of EZH2 and affects the methylation of the SOCS3 promoter in hepatocellular carcinoma.
    Wei L; Liu Q; Huang Y; Liu Z; Zhao R; Li B; Zhang J; Sun C; Gao B; Ding X; Yu X; He J; Sun A; Qin Y
    Int J Biochem Cell Biol; 2020 Mar; 120():105685. PubMed ID: 31917284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
    Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
    Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
    J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
    Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
    J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer of zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1.
    Zhou J; Che J; Xu L; Yang W; Li Y; Zhou W; Zou S
    Bioengineered; 2022 Mar; 13(3):5737-5755. PubMed ID: 35184652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling.
    Khan H; Ni Z; Feng H; Xing Y; Wu X; Huang D; Chen L; Niu Y; Shi G
    Phytomedicine; 2021 Oct; 91():153706. PubMed ID: 34517264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
    Li Q; Li B; Dong C; Wang Y; Li Q
    Eur J Pharmacol; 2017 Nov; 815():173-180. PubMed ID: 28928088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B.
    Yang F; Lv LZ; Cai QC; Jiang Y
    World J Gastroenterol; 2015 Dec; 21(47):13268-76. PubMed ID: 26715809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.